Novo Holdings A/S’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Novo Holdings A/S’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-592,794	Closed	-$18.4M	–	17
2017 Q3	$18.4M	Hold	592,794	–	–	2.4%	11
2017 Q2	$18.8M	Sell	592,794 -2,774,969	-82%	-$68.2M	2.24%	14
2017 Q1	$76.3M	Hold	3,367,763	–	–	8.12%	3
2016 Q4	$73.5M	Hold	3,367,763	–	–	7%	5
2016 Q3	$88.8M	Hold	3,367,763	–	–	7.88%	6
2016 Q2	$66.5M	Buy	+3,367,763	New	+$65.5M	6.98%	5

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Novo Holdings A/S's RETA Position: Q4 2017 in Review

Novo Holdings A/S sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2017, closing a stake of 592,794 shares — an estimated $18.4M sold.

Novo Holdings A/S first reported a position in RETA in Q2 2016 and held it in 6 quarters. The position peaked at $88.8M in Q3 2016. 89 funds tracked by Wall St. Rank hold RETA as of Q4 2017.

Novo Holdings A/S reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2017 after selling out during the quarter.
Novo Holdings A/S sold 592,794 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2017, an estimated $18.4M.
Novo Holdings A/S first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 6 quarters.
Novo Holdings A/S's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $88.8M in Q3 2016.
89 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2017.

Based on Novo Holdings A/S's 13F filing for Q4 2017, filed 14 Feb 2018.